Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 10:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Negative Symptoms in Schizophrenia Clear all
Terminated Phase 3 Interventional Results available

Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia

NCT01738698
View directory record Official record
Conditions
Schizophrenia
Interventions
SPD489 40mg, SPD489 100mg, SPD489 160mg, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Irving, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Jun 25, 2026, 10:23 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms

NCT01052103
View directory record Official record
Conditions
Schizophrenia
Interventions
LY2140023, Placebo, Standard of Care
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Garden Grove, California • Chicago, Illinois • Hoffman Estates, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Jun 25, 2026, 10:23 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia

NCT03397134
View directory record Official record
Conditions
Negative Symptoms of Schizophrenia
Interventions
Placebo Oral Tablet, Roluperidone 32 mg, Roluperidone 64 mg
Drug
Lead sponsor
Minerva Neurosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
13
States / cities
Rogers, Arkansas • Culver City, California • Garden Grove, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Jun 25, 2026, 10:23 PM EDT
Not yet recruiting Not applicable Interventional

Pilot Study of Sensor-Informed Smartphone-based Mental Health Interventions for Mood in Early Psychosis

NCT07503093
View directory record Official record
Conditions
Psychosis, Anxiety, Depression, Rumination
Interventions
Smartphone-based Mindfulness Exercise, Smartphone-based Psychoeducation, Neutral Control Message
Behavioral
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jun 25, 2026, 10:23 PM EDT
Completed Not applicable Interventional Results available

Improving Negative Symptoms of Psychosis In Real-world Environments

NCT02170051
View directory record Official record
Conditions
Schizophrenia
Interventions
CBSST-CCT, Goal focused supportive contact
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Jun 25, 2026, 10:23 PM EDT
Recruiting Not applicable Interventional

Transcranial Magnetic Stimulation (TMS) for Negative Symptoms in Schizophrenia Spectrum Disorders

NCT07290738
View directory record Official record
Conditions
Schizophrenia Spectrum Disorder
Interventions
TMS, sham
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Jun 25, 2026, 10:23 PM EDT
Completed Phase 3 Interventional

An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia

NCT06067984
View directory record Official record
Conditions
Schizophrenia, Negative Symptoms in Schizophrenia
Interventions
Study App
Device
Lead sponsor
Click Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 25, 2026, 10:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Brain Stimulation, Clinical Symptoms and Cognition

NCT05053451
View directory record Official record
Conditions
Schizophrenia
Interventions
Transcranial Direct Current Stimulation
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Jun 25, 2026, 10:23 PM EDT
Completed Phase 2 Interventional Results available

Safety and Effectiveness of D-serine in Schizophrenia

NCT00322023
View directory record Official record
Conditions
Schizophrenia
Interventions
D-serine
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 60 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
New Haven, Connecticut • Glen Oaks, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Jun 25, 2026, 10:23 PM EDT
Completed Not applicable Interventional

Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms

NCT00169988
View directory record Official record
Conditions
Prodromal Schizophrenia, Psychotic Disorders
Interventions
risperidone, sertraline-primary
Drug
Lead sponsor
Northwell Health
Other
Eligibility
12 Years to 22 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2009 · Synced Jun 25, 2026, 10:23 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia

NCT01192880
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Bitopertin, Antipsychotics
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
27
States / cities
Costa Mesa, California • Escondido, California • Granada Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2017 · Synced Jun 25, 2026, 10:23 PM EDT
Terminated Phase 3 Interventional Results available

SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia

NCT01760889
View directory record Official record
Conditions
Schizophrenia
Interventions
SPD489 low dose range (40mg, 80mg, and 100mg), SPD489 high dose range (120mg, 140mg and 160mg), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
4
States / cities
Miami Springs, Florida • O'Fallon, Missouri • Saint Charles, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Jun 25, 2026, 10:23 PM EDT
Terminated Phase 2 Interventional Results available

Treatment of Negative Symptoms of Schizophrenia With Transcranial Magnetic Stimulation (TMS)

NCT00517075
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Transcranial Magnetic Stimulation (TMS), repetitive transcranial magnetic stimulation
Device
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Jun 25, 2026, 10:23 PM EDT
Completed Phase 4 Interventional

Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine

NCT02505477
View directory record Official record
Conditions
Schizophrenia, Cognitive Deficits, Schizophrenia; Negative Type
Interventions
N-acetylcysteine, Treatment as Usual
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 14, 2023 · Synced Jun 25, 2026, 10:23 PM EDT
Completed Phase 2 Interventional Results available

Pregnenolone for Cognitive and Negative Symptoms in Schizophrenia

NCT00728728
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Dietary Supplement: Pregnenolone, Placebo
Drug · Dietary Supplement
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Jun 25, 2026, 10:23 PM EDT
Completed Phase 4 Interventional Results available

Folate Supplementation in Schizophrenia

NCT00249288
View directory record Official record
Conditions
Schizophrenia
Interventions
Folate, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 68 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Jun 25, 2026, 10:23 PM EDT
Completed Not applicable Interventional

Mobile CBT for Negative Symptoms

NCT03621774
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Mobile-assisted CBT-informed Skills Training, Supportive Contact
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 60 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Jun 25, 2026, 10:23 PM EDT
Completed Phase 3 Interventional

Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia

NCT05838625
View directory record Official record
Conditions
Schizophrenia
Interventions
CT-155, Digital Control
Device
Lead sponsor
Click Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
54
States / cities
Chandler, Arizona • Phoenix, Arizona • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jun 25, 2026, 10:23 PM EDT
Completed Phase 3 Interventional

A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)

NCT01192906
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, bitopertin [RO4917838]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
21
States / cities
Carson, California • Oceanside, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jun 25, 2026, 10:23 PM EDT
Terminated Not applicable Interventional Results available

Using Transcranial Magnetic Stimulation (TMS) to Understand 'Negative' Symptoms of Schizophrenia

NCT03648268
View directory record Official record
Conditions
Schizophrenia, Negative Type; Schizophrenic, Schizo Affective Disorder
Interventions
repetitive Transcranial Magnetic Stimulation (rTMS)
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jun 25, 2026, 10:23 PM EDT
Completed Phase 2Phase 3 Interventional

Adjunctive Treatment for Decreasing Symptoms of Schizophrenia

NCT00222235
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
d-cycloserine, glycine, placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 54 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Glen Oaks, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Jun 25, 2026, 10:23 PM EDT
Terminated Not applicable Interventional Results available

Treating Refractory Schizophrenia With rTMS

NCT02242578
View directory record Official record
Conditions
Schizophrenia
Interventions
1 Hz rTMS, 10 Hz rTMS
Device
Lead sponsor
Seton Healthcare Family
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced Jun 25, 2026, 10:23 PM EDT
Completed Not applicable Interventional Results available

Clinical Trial of Dipyridamole in Schizophrenia

NCT00349973
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Dipyridamole, Olanzapine
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2019 · Synced Jun 25, 2026, 10:23 PM EDT
Completed Not applicable Interventional Results available

Impact of Inflammation on Reward Circuits, Motivational Deficits and Negative Symptoms in Schizophrenia

NCT03818516
View directory record Official record
Conditions
Schizophrenia
Interventions
Oral Glucose Tolerance Test (OGTT)
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 59 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Jun 25, 2026, 10:23 PM EDT